Clinical Development

• NIAMS FY26 Funding Sign On

  May 08, 2025 Congress Clinical Development , Congress , Research Funding
  Read Statement

• Written Comment for Senate Appropriations Hearing on U.S. Biomedical Innovation

  April 29, 2025 Congress Regulatory Policy , Clinical Development , Congress , Research Funding , New Technologies
  Read Statement

• ARPA-H FY26 Funding Sign On

  April 23, 2025 Congress Clinical Development , Congress , Research Funding
  Read Statement

• Ad Hoc Medical Research Group NIH Funding Sign On

  April 07, 2025 Congress Clinical Development , Congress , Research Funding
  Read Statement

• Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics

  March 06, 2025 FDA Regulatory Policy , Clinical Development , FDA Guidance
  Read Statement

• R!A NIH Funding Sign On

  February 25, 2025 Congress Clinical Development , Congress , Research Funding
  Read Statement

• Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products

  February 17, 2025 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges

  January 29, 2025 Position Paper Clinical Development , Payment Policy
  Read Statement

• Optimizing Regulatory Frameworks for Gene Therapies in Rare Diseases: Challenges and solutions

  December 12, 2024 Position Paper Regulatory Policy , Clinical Development , CMC
  Read Statement

• Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies

  September 26, 2024 FDA Regulatory Policy , Clinical Development , Bioethics , FDA Guidance
  Read Statement

• Platform Technology Designation Program for Drug Development

  August 27, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Request for Information from Stakeholders on the Enacted Cures 2.0 Act

  August 02, 2024 Congress Regulatory Policy , Clinical Development , Research Funding , New Technologies
  Read Statement

• Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products

  July 29, 2024 FDA Regulatory Policy , Clinical Development , FDA Guidance
  Read Statement

• Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products

  July 26, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

• Comments on Predecisional Draft NCATS Strategic Plan 2024- 2029 

  June 14, 2024 Miscellaneous Regulatory Policy , Clinical Development , CMC , Research Funding , New Technologies , NBS
  Read Statement

• Potency Assurance for Cellular and Gene Therapy Products

  March 26, 2024 FDA Regulatory Policy , Clinical Development , CMC , FDA Guidance
  Read Statement

  1 2 3 4